Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb)

Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb): a Prospective Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02847507

Acronym

VIhVhEpb

Enrollment

307

Registered

2016-07-28

Start date

2016-07-31

Completion date

2018-01-31

Last updated

2018-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis E, HIV

Keywords

HIV, Hepatitis E

Brief summary

Study of seroprevalence of hepatitis E among HIV positive patient in Basque country, France in 2016.

Detailed description

Study of seroprevalence of hepatitis E among patient followed and treated in centre Hospitalier de la Côte Basque for HIV infections. Study of acquisition of hepatitis E , and determination of liver status using fibrotest in co-infected patients with hepatis C and / or B.

Interventions

None listed

Study design

Observational model

ECOLOGIC_OR_COMMUNITY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* HIV positive \> 18

Exclusion criteria

* patient refusal for participation

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of immunoglobulin M (IgM) and Immunoglobulin G (IgG) for hepatitis E in blood sample of each patients. Positive sample for both IgM and IgG will be confirmed using polymerase chain reaction (PCR) techniques	6 months time period	Blood samples will be tested for specific immunoglobulins against hepatitis E virus

Secondary

Measure	Time frame	Description
fibrotest score	6 months time period	patients infected with hepatitis B or hepatitis C viruses will have their liver status determined using fibrotest score.

Countries

France

Outcome results